BFM
TCRX icon

Boothbay Fund Management’s TScan Therapeutics TCRX Stock Holding History

Boothbay Fund Management’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-24,363
Closed -$35.3K – 2156
2025
Q2 		$35.3K Buy
24,363
+8,121
+50% +$11.7K ﹤0.01% 1374
2025
Q1 		$22.4K Buy
+16,242
New +$35.1K ﹤0.01% 1329
2024
Q1 		– Sell
-13,293
Closed -$77.5K – 1924
2023
Q4 		$77.5K Buy
+13,293
New +$60.9K ﹤0.01% 1462

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Boothbay Fund Management's TCRX Position: Q3 2025 in Review

Boothbay Fund Management sold out of TScan Therapeutics (TCRX) in Q3 2025, closing a stake of 24,363 shares — an estimated $35.3K sold.

Boothbay Fund Management first reported a position in TCRX in Q4 2023 and held it in 3 quarters. The position peaked at $77.5K in Q4 2023. 73 funds tracked by Wall St. Rank hold TCRX as of Q3 2025.

  • Boothbay Fund Management reported no remaining TScan Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 24,363 TScan Therapeutics shares in Q3 2025, an estimated $35.3K.
  • Boothbay Fund Management first reported a position in TScan Therapeutics in Q4 2023 and held it in 3 quarters.
  • Boothbay Fund Management's TScan Therapeutics position peaked at $77.5K in Q4 2023.
  • 73 funds tracked by Wall St. Rank held TScan Therapeutics as of Q3 2025.

Based on Boothbay Fund Management's 13F filing for Q3 2025, filed 14 Nov 2025.